Global Adalimumab (Humira) and Biosimilar Market Research Report 2023

Adalimumab (Humira) and Biosimilar Market

Adalimumab is a tumor necrosis factor (TNF) blocker that reduces the effects of a substance in the body that can cause inflammation.

Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Adalimumab (Humira) and Biosimilar market research.

The expiration of patents for adalimumab (Humira) has emerged as a significant driver in the biosimilar market. Adalimumab is a widely used biologic medication for autoimmune diseases. The patent expiry allows for the entry of biosimilar versions of Humira, which are highly similar and offer a more cost-effective alternative. This increased competition fosters price reduction and improved accessibility for patients, addressing the growing demand for affordable treatments. Furthermore, regulatory support for biosimilars has further bolstered their adoption, ensuring safety, efficacy, and quality. Overall, the patent expiration and regulatory support are key drivers propelling the adalimumab biosimilar market forward.

Report Scope

This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Adalimumab (Humira) and Biosimilar market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.

Scope of Adalimumab (Humira) and Biosimilar Market Report

1.1 Product Overview and Scope of Adalimumab (Humira) and Biosimilar

1.2 Adalimumab (Humira) and Biosimilar Segment by Type

1.2.1 Global Adalimumab (Humira) and Biosimilar Market Value Comparison by Type (2023-2029)

1.2.2 Syringe

1.2.3 Pen

1.3 Adalimumab (Humira) and Biosimilar Segment by Application

1.3.1 Global Adalimumab (Humira) and Biosimilar Market Value by Application: (2023-2029)

1.3.2 Ankylosing Spondylitis

1.3.3 Rheumatoid Arthritis

1.3.4 Crohn’s Disease

1.3.5 Other

1.4 Global Adalimumab (Humira) and Biosimilar Market Size Estimates and Forecasts

1.4.1 Global Adalimumab (Humira) and Biosimilar Revenue 2018-2029

1.4.2 Global Adalimumab (Humira) and Biosimilar Sales 2018-2029

1.4.3 Global Adalimumab (Humira) and Biosimilar Market Average Price (2018-2029)

1.5 Assumptions and Limitations

2.1 Global Adalimumab (Humira) and Biosimilar Sales Market Share by Manufacturers (2018-2023)

2.2 Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Manufacturers (2018-2023)

2.3 Global Adalimumab (Humira) and Biosimilar Average Price by Manufacturers (2018-2023)

2.4 Global Adalimumab (Humira) and Biosimilar Industry Ranking 2021 VS 2022 VS 2023

2.5 Global Key Manufacturers of Adalimumab (Humira) and Biosimilar, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Adalimumab (Humira) and Biosimilar, Product Type & Application

2.7 Adalimumab (Humira) and Biosimilar Market Competitive Situation and Trends

2.7.1 Adalimumab (Humira) and Biosimilar Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Adalimumab (Humira) and Biosimilar Players Market Share by Revenue

2.7.3 Global Adalimumab (Humira) and Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3.1 Global Adalimumab (Humira) and Biosimilar Market Size by Region: 2018 Versus 2022 Versus 2029

3.2 Global Adalimumab (Humira) and Biosimilar Global Adalimumab (Humira) and Biosimilar Sales by Region: 2018-2029

3.2.1 Global Adalimumab (Humira) and Biosimilar Sales by Region: 2018-2023

3.2.2 Global Adalimumab (Humira) and Biosimilar Sales by Region: 2024-2029

3.3 Global Adalimumab (Humira) and Biosimilar Global Adalimumab (Humira) and Biosimilar Revenue by Region: 2018-2029

3.3.1 Global Adalimumab (Humira) and Biosimilar Revenue by Region: 2018-2023

3.3.2 Global Adalimumab (Humira) and Biosimilar Revenue by Region: 2024-2029

3.4 North America Adalimumab (Humira) and Biosimilar Market Facts & Figures by Country

3.4.1 North America Adalimumab (Humira) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029

3.4.2 North America Adalimumab (Humira) and Biosimilar Sales by Country (2018-2029)

3.4.3 North America Adalimumab (Humira) and Biosimilar Revenue by Country (2018-2029)

3.4.4 United States

3.4.5 Canada

3.5 Europe Adalimumab (Humira) and Biosimilar Market Facts & Figures by Country

3.5.1 Europe Adalimumab (Humira) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029

3.5.2 Europe Adalimumab (Humira) and Biosimilar Sales by Country (2018-2029)

3.5.3 Europe Adalimumab (Humira) and Biosimilar Revenue by Country (2018-2029)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Adalimumab (Humira) and Biosimilar Market Facts & Figures by Country

3.6.1 Asia Pacific Adalimumab (Humira) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029

3.6.2 Asia Pacific Adalimumab (Humira) and Biosimilar Sales by Country (2018-2029)

3.6.3 Asia Pacific Adalimumab (Humira) and Biosimilar Revenue by Country (2018-2029)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America Adalimumab (Humira) and Biosimilar Market Facts & Figures by Country

3.7.1 Latin America Adalimumab (Humira) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029

3.7.2 Latin America Adalimumab (Humira) and Biosimilar Sales by Country (2018-2029)

3.7.3 Latin America Adalimumab (Humira) and Biosimilar Revenue by Country (2018-2029)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.7.7 Colombia

3.8 Middle East and Africa Adalimumab (Humira) and Biosimilar Market Facts & Figures by Country

3.8.1 Middle East and Africa Adalimumab (Humira) and Biosimilar Market Size by Country: 2018 VS 2022 VS 2029

3.8.2 Middle East and Africa Adalimumab (Humira) and Biosimilar Sales by Country (2018-2029)

3.8.3 Middle East and Africa Adalimumab (Humira) and Biosimilar Revenue by Country (2018-2029)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4.1 Global Adalimumab (Humira) and Biosimilar Sales by Type (2018-2029)

4.1.1 Global Adalimumab (Humira) and Biosimilar Sales by Type (2018-2023)

4.1.2 Global Adalimumab (Humira) and Biosimilar Sales by Type (2024-2029)

4.1.3 Global Adalimumab (Humira) and Biosimilar Sales Market Share by Type (2018-2029)

4.2 Global Adalimumab (Humira) and Biosimilar Revenue by Type (2018-2029)

4.2.1 Global Adalimumab (Humira) and Biosimilar Revenue by Type (2018-2023)

4.2.2 Global Adalimumab (Humira) and Biosimilar Revenue by Type (2024-2029)

4.2.3 Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Type (2018-2029)

4.3 Global Adalimumab (Humira) and Biosimilar Price by Type (2018-2029)

5.1 Global Adalimumab (Humira) and Biosimilar Sales by Application (2018-2029)

5.1.1 Global Adalimumab (Humira) and Biosimilar Sales by Application (2018-2023)

5.1.2 Global Adalimumab (Humira) and Biosimilar Sales by Application (2024-2029)

5.1.3 Global Adalimumab (Humira) and Biosimilar Sales Market Share by Application (2018-2029)

5.2 Global Adalimumab (Humira) and Biosimilar Revenue by Application (2018-2029)

5.2.1 Global Adalimumab (Humira) and Biosimilar Revenue by Application (2018-2023)

5.2.2 Global Adalimumab (Humira) and Biosimilar Revenue by Application (2024-2029)

5.2.3 Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Application (2018-2029)

5.3 Global Adalimumab (Humira) and Biosimilar Price by Application (2018-2029)

6.1 AbbVie

6.1.1 AbbVie Corporation Information

6.1.2 AbbVie Description and Business Overview

6.1.3 AbbVie Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)

6.1.4 AbbVie Adalimumab (Humira) and Biosimilar Product Portfolio

6.1.5 AbbVie Recent Developments/Updates

6.2 Eisai

6.2.1 Eisai Corporation Information

6.2.2 Eisai Description and Business Overview

6.2.3 Eisai Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)

6.2.4 Eisai Adalimumab (Humira) and Biosimilar Product Portfolio

6.2.5 Eisai Recent Developments/Updates

6.3 Cadila Healthcare

6.3.1 Cadila Healthcare Corporation Information

6.3.2 Cadila Healthcare Description and Business Overview

6.3.3 Cadila Healthcare Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)

6.3.4 Cadila Healthcare Adalimumab (Humira) and Biosimilar Product Portfolio

6.3.5 Cadila Healthcare Recent Developments/Updates

6.4 Torrent Pharmaceuticals

6.4.1 Torrent Pharmaceuticals Corporation Information

6.4.2 Torrent Pharmaceuticals Description and Business Overview

6.4.3 Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)

6.4.4 Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Product Portfolio

6.4.5 Torrent Pharmaceuticals Recent Developments/Updates

6.5 Amgen

6.5.1 Amgen Corporation Information

6.5.2 Amgen Description and Business Overview

6.5.3 Amgen Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)

6.5.4 Amgen Adalimumab (Humira) and Biosimilar Product Portfolio

6.5.5 Amgen Recent Developments/Updates

6.6 Boehringer Ingelheim

6.6.1 Boehringer Ingelheim Corporation Information

6.6.2 Boehringer Ingelheim Description and Business Overview

6.6.3 Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)

6.6.4 Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Product Portfolio

6.6.5 Boehringer Ingelheim Recent Developments/Updates

6.7 Novartis

6.6.1 Novartis Corporation Information

6.6.2 Novartis Description and Business Overview

6.6.3 Novartis Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)

6.4.4 Novartis Adalimumab (Humira) and Biosimilar Product Portfolio

6.7.5 Novartis Recent Developments/Updates

6.8 Samsung Bioepis

6.8.1 Samsung Bioepis Corporation Information

6.8.2 Samsung Bioepis Description and Business Overview

6.8.3 Samsung Bioepis Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)

6.8.4 Samsung Bioepis Adalimumab (Humira) and Biosimilar Product Portfolio

6.8.5 Samsung Bioepis Recent Developments/Updates

6.9 Viatris

6.9.1 Viatris Corporation Information

6.9.2 Viatris Description and Business Overview

6.9.3 Viatris Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)

6.9.4 Viatris Adalimumab (Humira) and Biosimilar Product Portfolio

6.9.5 Viatris Recent Developments/Updates

6.10 Pfizer

6.10.1 Pfizer Corporation Information

6.10.2 Pfizer Description and Business Overview

6.10.3 Pfizer Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)

6.10.4 Pfizer Adalimumab (Humira) and Biosimilar Product Portfolio

6.10.5 Pfizer Recent Developments/Updates

6.11 Fresenius Kabi

6.11.1 Fresenius Kabi Corporation Information

6.11.2 Fresenius Kabi Adalimumab (Humira) and Biosimilar Description and Business Overview

6.11.3 Fresenius Kabi Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)

6.11.4 Fresenius Kabi Adalimumab (Humira) and Biosimilar Product Portfolio

6.11.5 Fresenius Kabi Recent Developments/Updates

6.12 Coherus

6.12.1 Coherus Corporation Information

6.12.2 Coherus Adalimumab (Humira) and Biosimilar Description and Business Overview

6.12.3 Coherus Adalimumab (Humira) and Biosimilar Sales, Revenue and Gross Margin (2018-2023)

6.12.4 Coherus Adalimumab (Humira) and Biosimilar Product Portfolio

6.12.5 Coherus Recent Developments/Updates

7.1 Adalimumab (Humira) and Biosimilar Industry Chain Analysis

7.2 Adalimumab (Humira) and Biosimilar Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Adalimumab (Humira) and Biosimilar Production Mode & Process

7.4 Adalimumab (Humira) and Biosimilar Sales and Marketing

7.4.1 Adalimumab (Humira) and Biosimilar Sales Channels

7.4.2 Adalimumab (Humira) and Biosimilar Distributors

7.5 Adalimumab (Humira) and Biosimilar Customers

8.1 Adalimumab (Humira) and Biosimilar Industry Trends

8.2 Adalimumab (Humira) and Biosimilar Market Drivers

8.3 Adalimumab (Humira) and Biosimilar Market Challenges

8.4 Adalimumab (Humira) and Biosimilar Market Restraints

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

List of Tables

    Table 1. Global Adalimumab (Humira) and Biosimilar Market Value Comparison by Type (2023-2029) & (US$ Million)

    Table 2. Global Adalimumab (Humira) and Biosimilar Market Value Comparison by Application (2023-2029) & (US$ Million)

    Table 3. Global Adalimumab (Humira) and Biosimilar Market Competitive Situation by Manufacturers in 2022

    Table 4. Global Adalimumab (Humira) and Biosimilar Sales (K Units) of Key Manufacturers (2018-2023)

    Table 5. Global Adalimumab (Humira) and Biosimilar Sales Market Share by Manufacturers (2018-2023)

    Table 6. Global Adalimumab (Humira) and Biosimilar Revenue (US$ Million) by Manufacturers (2018-2023)

    Table 7. Global Adalimumab (Humira) and Biosimilar Revenue Share by Manufacturers (2018-2023)

    Table 8. Global Market Adalimumab (Humira) and Biosimilar Average Price (US$/Unit) of Key Manufacturers (2018-2023)

    Table 9. Global Key Players of Adalimumab (Humira) and Biosimilar, Industry Ranking, 2021 VS 2022 VS 2023

    Table 10. Global Key Manufacturers of Adalimumab (Humira) and Biosimilar, Manufacturing Sites & Headquarters

    Table 11. Global Key Manufacturers of Adalimumab (Humira) and Biosimilar, Product Type & Application

    Table 12. Global Key Manufacturers of Adalimumab (Humira) and Biosimilar, Date of Enter into This Industry

    Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

    Table 14. Global Adalimumab (Humira) and Biosimilar by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adalimumab (Humira) and Biosimilar as of 2022)

    Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

    Table 16. Global Adalimumab (Humira) and Biosimilar Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Table 17. Global Adalimumab (Humira) and Biosimilar Sales by Region (2018-2023) & (K Units)

    Table 18. Global Adalimumab (Humira) and Biosimilar Sales Market Share by Region (2018-2023)

    Table 19. Global Adalimumab (Humira) and Biosimilar Sales by Region (2024-2029) & (K Units)

    Table 20. Global Adalimumab (Humira) and Biosimilar Sales Market Share by Region (2024-2029)

    Table 21. Global Adalimumab (Humira) and Biosimilar Revenue by Region (2018-2023) & (US$ Million)

    Table 22. Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Region (2018-2023)

    Table 23. Global Adalimumab (Humira) and Biosimilar Revenue by Region (2024-2029) & (US$ Million)

    Table 24. Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Region (2024-2029)

    Table 25. North America Adalimumab (Humira) and Biosimilar Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

    Table 26. North America Adalimumab (Humira) and Biosimilar Sales by Country (2018-2023) & (K Units)

    Table 27. North America Adalimumab (Humira) and Biosimilar Sales by Country (2024-2029) & (K Units)

    Table 28. North America Adalimumab (Humira) and Biosimilar Revenue by Country (2018-2023) & (US$ Million)

    Table 29. North America Adalimumab (Humira) and Biosimilar Revenue by Country (2024-2029) & (US$ Million)

    Table 30. Europe Adalimumab (Humira) and Biosimilar Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

    Table 31. Europe Adalimumab (Humira) and Biosimilar Sales by Country (2018-2023) & (K Units)

    Table 32. Europe Adalimumab (Humira) and Biosimilar Sales by Country (2024-2029) & (K Units)

    Table 33. Europe Adalimumab (Humira) and Biosimilar Revenue by Country (2018-2023) & (US$ Million)

    Table 34. Europe Adalimumab (Humira) and Biosimilar Revenue by Country (2024-2029) & (US$ Million)

    Table 35. Asia Pacific Adalimumab (Humira) and Biosimilar Revenue by Region: 2018 VS 2022 VS 2029 (US$ Million)

    Table 36. Asia Pacific Adalimumab (Humira) and Biosimilar Sales by Region (2018-2023) & (K Units)

    Table 37. Asia Pacific Adalimumab (Humira) and Biosimilar Sales by Region (2024-2029) & (K Units)

    Table 38. Asia Pacific Adalimumab (Humira) and Biosimilar Revenue by Region (2018-2023) & (US$ Million)

    Table 39. Asia Pacific Adalimumab (Humira) and Biosimilar Revenue by Region (2024-2029) & (US$ Million)

    Table 40. Latin America Adalimumab (Humira) and Biosimilar Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

    Table 41. Latin America Adalimumab (Humira) and Biosimilar Sales by Country (2018-2023) & (K Units)

    Table 42. Latin America Adalimumab (Humira) and Biosimilar Sales by Country (2024-2029) & (K Units)

    Table 43. Latin America Adalimumab (Humira) and Biosimilar Revenue by Country (2018-2023) & (US$ Million)

    Table 44. Latin America Adalimumab (Humira) and Biosimilar Revenue by Country (2024-2029) & (US$ Million)

    Table 45. Middle East & Africa Adalimumab (Humira) and Biosimilar Revenue by Country: 2018 VS 2022 VS 2029 (US$ Million)

    Table 46. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales by Country (2018-2023) & (K Units)

    Table 47. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales by Country (2024-2029) & (K Units)

    Table 48. Middle East & Africa Adalimumab (Humira) and Biosimilar Revenue by Country (2018-2023) & (US$ Million)

    Table 49. Middle East & Africa Adalimumab (Humira) and Biosimilar Revenue by Country (2024-2029) & (US$ Million)

    Table 50. Global Adalimumab (Humira) and Biosimilar Sales (K Units) by Type (2018-2023)

    Table 51. Global Adalimumab (Humira) and Biosimilar Sales (K Units) by Type (2024-2029)

    Table 52. Global Adalimumab (Humira) and Biosimilar Sales Market Share by Type (2018-2023)

    Table 53. Global Adalimumab (Humira) and Biosimilar Sales Market Share by Type (2024-2029)

    Table 54. Global Adalimumab (Humira) and Biosimilar Revenue (US$ Million) by Type (2018-2023)

    Table 55. Global Adalimumab (Humira) and Biosimilar Revenue (US$ Million) by Type (2024-2029)

    Table 56. Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Type (2018-2023)

    Table 57. Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Type (2024-2029)

    Table 58. Global Adalimumab (Humira) and Biosimilar Price (US$/Unit) by Type (2018-2023)

    Table 59. Global Adalimumab (Humira) and Biosimilar Price (US$/Unit) by Type (2024-2029)

    Table 60. Global Adalimumab (Humira) and Biosimilar Sales (K Units) by Application (2018-2023)

    Table 61. Global Adalimumab (Humira) and Biosimilar Sales (K Units) by Application (2024-2029)

    Table 62. Global Adalimumab (Humira) and Biosimilar Sales Market Share by Application (2018-2023)

    Table 63. Global Adalimumab (Humira) and Biosimilar Sales Market Share by Application (2024-2029)

    Table 64. Global Adalimumab (Humira) and Biosimilar Revenue (US$ Million) by Application (2018-2023)

    Table 65. Global Adalimumab (Humira) and Biosimilar Revenue (US$ Million) by Application (2024-2029)

    Table 66. Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Application (2018-2023)

    Table 67. Global Adalimumab (Humira) and Biosimilar Revenue Market Share by Application (2024-2029)

    Table 68. Global Adalimumab (Humira) and Biosimilar Price (US$/Unit) by Application (2018-2023)

    Table 69. Global Adalimumab (Humira) and Biosimilar Price (US$/Unit) by Application (2024-2029)

    Table 70. AbbVie Corporation Information

    Table 71. AbbVie Description and Business Overview

    Table 72. AbbVie Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 73. AbbVie Adalimumab (Humira) and Biosimilar Product

    Table 74. AbbVie Recent Developments/Updates

    Table 75. Eisai Corporation Information

    Table 76. Eisai Description and Business Overview

    Table 77. Eisai Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 78. Eisai Adalimumab (Humira) and Biosimilar Product

    Table 79. Eisai Recent Developments/Updates

    Table 80. Cadila Healthcare Corporation Information

    Table 81. Cadila Healthcare Description and Business Overview

    Table 82. Cadila Healthcare Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 83. Cadila Healthcare Adalimumab (Humira) and Biosimilar Product

    Table 84. Cadila Healthcare Recent Developments/Updates

    Table 85. Torrent Pharmaceuticals Corporation Information

    Table 86. Torrent Pharmaceuticals Description and Business Overview

    Table 87. Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 88. Torrent Pharmaceuticals Adalimumab (Humira) and Biosimilar Product

    Table 89. Torrent Pharmaceuticals Recent Developments/Updates

    Table 90. Amgen Corporation Information

    Table 91. Amgen Description and Business Overview

    Table 92. Amgen Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 93. Amgen Adalimumab (Humira) and Biosimilar Product

    Table 94. Amgen Recent Developments/Updates

    Table 95. Boehringer Ingelheim Corporation Information

    Table 96. Boehringer Ingelheim Description and Business Overview

    Table 97. Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 98. Boehringer Ingelheim Adalimumab (Humira) and Biosimilar Product

    Table 99. Boehringer Ingelheim Recent Developments/Updates

    Table 100. Novartis Corporation Information

    Table 101. Novartis Description and Business Overview

    Table 102. Novartis Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 103. Novartis Adalimumab (Humira) and Biosimilar Product

    Table 104. Novartis Recent Developments/Updates

    Table 105. Samsung Bioepis Corporation Information

    Table 106. Samsung Bioepis Description and Business Overview

    Table 107. Samsung Bioepis Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 108. Samsung Bioepis Adalimumab (Humira) and Biosimilar Product

    Table 109. Samsung Bioepis Recent Developments/Updates

    Table 110. Viatris Corporation Information

    Table 111. Viatris Description and Business Overview

    Table 112. Viatris Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 113. Viatris Adalimumab (Humira) and Biosimilar Product

    Table 114. Viatris Recent Developments/Updates

    Table 115. Pfizer Corporation Information

    Table 116. Pfizer Description and Business Overview

    Table 117. Pfizer Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 118. Pfizer Adalimumab (Humira) and Biosimilar Product

    Table 119. Pfizer Recent Developments/Updates

    Table 120. Fresenius Kabi Corporation Information

    Table 121. Fresenius Kabi Description and Business Overview

    Table 122. Fresenius Kabi Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 123. Fresenius Kabi Adalimumab (Humira) and Biosimilar Product

    Table 124. Fresenius Kabi Recent Developments/Updates

    Table 125. Coherus Corporation Information

    Table 126. Coherus Description and Business Overview

    Table 127. Coherus Adalimumab (Humira) and Biosimilar Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2018-2023)

    Table 128. Coherus Adalimumab (Humira) and Biosimilar Product

    Table 129. Coherus Recent Developments/Updates

    Table 130. Key Raw Materials Lists

    Table 131. Raw Materials Key Suppliers Lists

    Table 132. Adalimumab (Humira) and Biosimilar Distributors List

    Table 133. Adalimumab (Humira) and Biosimilar Customers List

    Table 134. Adalimumab (Humira) and Biosimilar Market Trends

    Table 135. Adalimumab (Humira) and Biosimilar Market Drivers

    Table 136. Adalimumab (Humira) and Biosimilar Market Challenges

    Table 137. Adalimumab (Humira) and Biosimilar Market Restraints

    Table 138. Research Programs/Design for This Report

    Table 139. Key Data Information from Secondary Sources

    Table 140. Key Data Information from Primary Sources

List of Figures

    Figure 1. Product Picture of Adalimumab (Humira) and Biosimilar

    Figure 2. Global Adalimumab (Humira) and Biosimilar Market Value Comparison by Type (2023-2029) & (US$ Million)

    Figure 3. Global Adalimumab (Humira) and Biosimilar Market Share by Type in 2022 & 2029

    Figure 4. Syringe Product Picture

    Figure 5. Pen Product Picture

    Figure 6. Global Adalimumab (Humira) and Biosimilar Market Value Comparison by Application (2023-2029) & (US$ Million)

    Figure 7. Global Adalimumab (Humira) and Biosimilar Market Share by Application in 2022 & 2029

    Figure 8. Ankylosing Spondylitis

    Figure 9. Rheumatoid Arthritis

    Figure 10. Crohn’s Disease

    Figure 11. Other

    Figure 12. Global Adalimumab (Humira) and Biosimilar Revenue, (US$ Million), 2018 VS 2022 VS 2029

    Figure 13. Global Adalimumab (Humira) and Biosimilar Market Size (2018-2029) & (US$ Million)

    Figure 14. Global Adalimumab (Humira) and Biosimilar Sales (2018-2029) & (K Units)

    Figure 15. Global Adalimumab (Humira) and Biosimilar Average Price (US$/Unit) & (2018-2029)

    Figure 16. Adalimumab (Humira) and Biosimilar Report Years Considered

    Figure 17. Adalimumab (Humira) and Biosimilar Sales Share by Manufacturers in 2022

    Figure 18. Global Adalimumab (Humira) and Biosimilar Revenue Share by Manufacturers in 2022

    Figure 19. The Global 5 and 10 Largest Adalimumab (Humira) and Biosimilar Players: Market Share by Revenue in 2022

    Figure 20. Adalimumab (Humira) and Biosimilar Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2018 VS 2022

    Figure 21. Global Adalimumab (Humira) and Biosimilar Market Size by Region (US$ Million): 2018 VS 2022 VS 2029

    Figure 22. North America Adalimumab (Humira) and Biosimilar Sales Market Share by Country (2018-2029)

    Figure 23. North America Adalimumab (Humira) and Biosimilar Revenue Market Share by Country (2018-2029)

    Figure 24. United States Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 25. Canada Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 26. Europe Adalimumab (Humira) and Biosimilar Sales Market Share by Country (2018-2029)

    Figure 27. Europe Adalimumab (Humira) and Biosimilar Revenue Market Share by Country (2018-2029)

    Figure 28. Germany Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 29. France Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 30. U.K. Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 31. Italy Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 32. Russia Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 33. Asia Pacific Adalimumab (Humira) and Biosimilar Sales Market Share by Region (2018-2029)

    Figure 34. Asia Pacific Adalimumab (Humira) and Biosimilar Revenue Market Share by Region (2018-2029)

    Figure 35. China Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 36. Japan Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 37. South Korea Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 38. India Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 39. Australia Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 40. China Taiwan Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 41. Southeast Asia Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 42. Latin America Adalimumab (Humira) and Biosimilar Sales Market Share by Country (2018-2029)

    Figure 43. Latin America Adalimumab (Humira) and Biosimilar Revenue Market Share by Country (2018-2029)

    Figure 44. Mexico Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 45. Brazil Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 46. Argentina Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 47. Colombia Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 48. Middle East & Africa Adalimumab (Humira) and Biosimilar Sales Market Share by Country (2018-2029)

    Figure 49. Middle East & Africa Adalimumab (Humira) and Biosimilar Revenue Market Share by Country (2018-2029)

    Figure 50. Turkey Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 51. Saudi Arabia Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 52. UAE Adalimumab (Humira) and Biosimilar Revenue Growth Rate (2018-2029) & (US$ Million)

    Figure 53. Global Sales Market Share of Adalimumab (Humira) and Biosimilar by Type (2018-2029)

    Figure 54. Global Revenue Market Share of Adalimumab (Humira) and Biosimilar by Type (2018-2029)

    Figure 55. Global Adalimumab (Humira) and Biosimilar Price (US$/Unit) by Type (2018-2029)

    Figure 56. Global Sales Market Share of Adalimumab (Humira) and Biosimilar by Application (2018-2029)

    Figure 57. Global Revenue Market Share of Adalimumab (Humira) and Biosimilar by Application (2018-2029)

    Figure 58. Global Adalimumab (Humira) and Biosimilar Price (US$/Unit) by Application (2018-2029)

    Figure 59. Adalimumab (Humira) and Biosimilar Value Chain

    Figure 60. Adalimumab (Humira) and Biosimilar Production Process

    Figure 61. Channels of Distribution (Direct Vs Distribution)

    Figure 62. Distributors Profiles

    Figure 63. Bottom-up and Top-down Approaches for This Report

    Figure 64. Data Triangulation

    Figure 65. Key Executives Interviewed